When the World Health Organization released its first malaria vaccine technology roadmap in 2006, it put the development of a partly effective vaccine by 2015 at the top of its list of priorities. With GlaxoSmithKline nearing that goal, WHO has revised its plan with new targets for 2030.
While anthrax, smallpox and other "category A" bioterrorism threats dominate the collective public consciousness, a larger pool of lower-priority agents are also a danger. Q fever falls into this second tier, but the U.S. government is still sufficiently concerned to gather researchers to talk vaccine development.
Israel's Oramed won a patent from the European Union for its oral insulin pill, giving the Jerusalem company a potential foothold in the diabetes market estimated to be worth about $14 billion by 2017, according to analysts.
Google made major waves two months ago when it landed former Genentech CEO Art Levinson to run its still-murky Calico offshoot. Now the biotech elder statesman is reuniting with his former chief medical officer, convincing Hal Barron to leave his post at Roche and oversee R&D at the nascent company.
AstraZeneca and its stilted R&D division aren't scheduled to move to Cambridge, U.K., until 2016, but the drugmaker can't wait to settle in at what it calls "one of the world's preeminent biosciences hotspots," planning to send an advance team of scientists to plant some collaborative seeds.
A team of researchers from Nottingham University in the U.K. have repurposed a bone-healing polymer to achieve something very different: delivery of cancer drugs to tumors in the brain after surgery.
Liquidia Technologies launched a new company this week with $25 million in Series A funding aimed at developing an extended-release glaucoma treatment that could last for several months after one injection.
Researchers in the U.K. are taking a hard line on the delivery of biologics to treat a variety of diseases using new delivery methods to get the large molecules safely past the cell membrane.
A small patch that delivers DNA-loaded nanoparticles may be the next step in bone regeneration, offering a new option for patients currently receiving repeated, painful injections.
Fresh off a $46 million funding round, Germany's immatics has inked a deal to collaborate with Roche on cancer therapies, signing an end-to-end agreement that could bring in more than $1 billion in milestones.